Author:
Lee SungKyung,Lee Jong Hyuk
Abstract
Ever since relevant bioengineering technologies have sufficiently matured to the platformizable commercialization stage, a slew of money has flocked to the cell and gene therapy market over the last few years, resulting in an abundance of clinical studies in the field. Newer modalities have brought up a string of regulatory and legislative tasks, such as developing guidelines and legislative rules to systematically regulate newer pharmaceutical products. Accordingly, another layer of legislation and guidelines tailored for cell and gene therapies has been introduced and is expected to evolve on par with technological progress. Furthermore, authorities have shifted to pricing and reimbursement policies that can share risks for cost and outcome among stakeholders altogether, such as developers and the government, while expanding the accessibility of patients to innovative cell and gene therapies. This review attempts to capture the salient regulatory features of the cell and gene therapy market in the context of South Korea and the European Union and points out where two sovereign entities currently stand on each policy element and how each tackles regulatory challenges. We can observe the converging trend where regulatory, pricing and reimbursement rules of adjoining countries in the supranational union or member countries of a consortium are getting more aligned. Evidently, concerted efforts to share regulatory science knowledge and embrace reference pricing have played their parts. The authors argue that policy priorities should be placed on initiatives to harmonize with other medical authorities to better the rights of patients and clear out the uncertainties of developers, ultimately to share and advance regulatory science and layout forward-looking policies at opportune times.
Subject
Public Health, Environmental and Occupational Health
Reference80 articles.
1. LeclercO
SuhendraM
TheL
What Are the Biotech Investment Themes That Will Shape the Industry? McKinsey & Company2022
2. Press Release from The 16th Health Insurance Policy Review Committee2022
3. American Society of Gene & Cell TherapyGene, Cell, & RNA Therapy Landscape, Q2 2022 Quarterly Data Report2022
4. The use of viral vectors in vaccine development;Travieso;Npj Vacc.,2022
5. LeeSK
LeeJH
10.1155/2022/9670992KIETCell Gene Therapy Market Analysis Policy Implications2022
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献